Literature DB >> 21665142

A lipid kinase cousin cooperates to promote cancer.

Brandon Beagle1, David A Fruman.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) are considered promising drug targets in oncology. In this issue of Cancer Cell, Schmid et al. demonstrate that the PI3Kγ isoform is required for inflammatory myeloid cells to traffic to tumors. Though tumor cells do not express PI3Kγ, selective inhibition of this isoform suppresses tumor growth and angiogenesis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21665142      PMCID： PMC3129267          DOI： 10.1016/j.ccr.2011.05.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 2.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Authors:  Michael C Schmid; Christie J Avraamides; Holly C Dippold; Irene Franco; Philippe Foubert; Lesley G Ellies; Lissette M Acevedo; Joan R E Manglicmot; Xiaodan Song; Wolfgang Wrasidlo; Sara L Blair; Mark H Ginsberg; David A Cheresh; Emilio Hirsch; Seth J Field; Judith A Varner
Journal:  Cancer Cell       Date:  2011-06-14       Impact factor: 31.743

Review 4.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity.

Authors:  Alberto Mantovani; Antonio Sica
Journal:  Curr Opin Immunol       Date:  2010-02-09       Impact factor: 7.486

Review 5.  Oncogenic PI3K and its role in cancer.

Authors:  Yardena Samuels; Kajsa Ericson
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

Review 6.  PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?

Authors:  Thomas Rückle; Matthias K Schwarz; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2006-10-13       Impact factor: 84.694

7.  CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Authors:  Brian J Lannutti; Sarah A Meadows; Sarah E M Herman; Adam Kashishian; Bart Steiner; Amy J Johnson; John C Byrd; Jeffrey W Tyner; Marc M Loriaux; Mike Deininger; Brian J Druker; Kamal D Puri; Roger G Ulrich; Neill A Giese
Journal:  Blood       Date:  2010-10-19       Impact factor: 22.113

8.  Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.

Authors:  Elisa Ciraolo; Manuela Iezzi; Romina Marone; Stefano Marengo; Claudia Curcio; Carlotta Costa; Ornella Azzolino; Cristiano Gonella; Cristina Rubinetto; Haiyan Wu; Walter Dastrù; Erica L Martin; Lorenzo Silengo; Fiorella Altruda; Emilia Turco; Letizia Lanzetti; Piero Musiani; Thomas Rückle; Christian Rommel; Jonathan M Backer; Guido Forni; Matthias P Wymann; Emilio Hirsch
Journal:  Sci Signal       Date:  2008-09-09       Impact factor: 8.192

9.  Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

Authors:  Shidong Jia; Zhenning Liu; Sen Zhang; Pixu Liu; Lei Zhang; Sang Hyun Lee; Jing Zhang; Sabina Signoretti; Massimo Loda; Thomas M Roberts; Jean J Zhao
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582
  10 in total
  6 in total

Review 1.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

2.  The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.

Authors:  Huey-En Tzeng; Lixin Yang; Kemin Chen; Yafan Wang; Yun-Ru Liu; Shiow-Lin Pan; Shikha Gaur; Shuya Hu; Yun Yen
Journal:  Oncotarget       Date:  2015-05-10

3.  Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells.

Authors:  Qiang Wang; Jian Mo; Chenchen Zhao; Kangmao Huang; Mingxuan Feng; Wenxin He; Jiying Wang; Shuai Chen; Zi'ang Xie; Jianjun Ma; Shunwu Fan
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

Review 4.  Function, Regulation and Biological Roles of PI3Kγ Variants.

Authors:  Bernd Nürnberg; Sandra Beer-Hammer
Journal:  Biomolecules       Date:  2019-08-30

5.  Cancer-Associated Fibroblast-Derived Exosomal miRNA-320a Promotes Macrophage M2 Polarization In Vitro by Regulating PTEN/PI3Kγ Signaling in Pancreatic Cancer.

Authors:  Mingkun Zhao; Aobo Zhuang; Yuan Fang
Journal:  J Oncol       Date:  2022-07-01       Impact factor: 4.501

6.  Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation.

Authors:  Junmei Cairns; Brooke L Fridley; Gregory D Jenkins; Yongxian Zhuang; Jia Yu; Liewei Wang
Journal:  EMBO Rep       Date:  2018-01-15       Impact factor: 8.807
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.